Cell Therapy Efficacy Assessment Using TGF-β and TSP-1 Thresholds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for evaluating the effectiveness of cell therapeutic agents, particularly for osteoarthritis, lack consistent procedures and techniques to verify therapeutic efficacy, especially due to variations in production conditions and environmental changes, making it difficult to ensure reliable treatment outcomes.
Innovation Solution
A method involving the preparation of transformed and untransformed mammalian cells, measuring TGF-β and thrombospondin 1 (TSP-1) expression levels, and determining effectiveness based on specific thresholds (0.65 ng/10^5 cells/24 hrs for TGF-β and 31 ng/10^5 cells/24 hrs for TSP-1) to establish a reliable quality control for cell therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cell therapeutic agents are produced under varying production conditions, then productivity is improved, but reliability of therapeutic efficacy deteriorates
Solution Approach 1:
The patent establishes specific parameter thresholds for TGF-β (0.65 ng/10^5 cells/24 hrs) and TSP-1 (31 ng/10^5 cells/24 hrs) expression levels as quality control criteria. By monitoring these biochemical parameters, the patent enables consistent verification of therapeutic efficacy across different production batches and conditions, resolving the contradiction between production flexibility and efficacy reliability
Solution Approach 2:
The patent implements a feedback mechanism where TGF-β and TSP-1 expression levels are measured and used to determine whether cell therapeutic agents meet effectiveness criteria. This feedback loop ensures that only agents with sufficient expression levels are approved for use, maintaining reliability while allowing productive variation in production processes
2Reliability
If quality control standards are established to verify therapeutic efficacy, then reliability is improved, but device complexity increases
Solution Approach 1:
The patent extracts and measures specific biochemical markers (TGF-β and TSP-1 expression levels) as independent quality indicators. By focusing on these discrete, measurable parameters rather than attempting to control all production variables, the patent simplifies the quality control process while maintaining high reliability in verifying therapeutic efficacy
Data Source
Figure 1~2
Figure 3a~3b
Figure 4
AI summary
The present invention provides a method for evaluating effectiveness of a cell therapeutic agent. When using TGF-β and/or TSP-1 expression level (s) in: (a) a first population of transformed mammalian cells with TGF-β; and (b) a second population of untransformed mammalian cells with the same gene, respectively, as a criterion for determining effectiveness of a cell therapeutic agent, and whether or not expression thereof, it is possible to definitely determine the therapeutic efficacy of each cell therapeutic agent prior to initiation of the treatment. In addition, since use of a cell therapeutic agent without therapeutic effects is avoided, undesired procedures and side effects may not be entailed.